LS
CHRS icon

Livforsakringsbolaget Skandia’s Coherus Oncology CHRS Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,300
Closed -$388K – 619
2021
Q4 		$388K Hold
24,300
– – 0.02% 318
2021
Q3 		$391K Hold
24,300
– – 0.02% 381
2021
Q2 		$336K Buy
+24,300
New +$344K 0.02% 448

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Livforsakringsbolaget Skandia's CHRS Position: Q1 2022 in Review

Livforsakringsbolaget Skandia sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 24,300 shares — an estimated $388K sold.

Livforsakringsbolaget Skandia first reported a position in CHRS in Q2 2021 and held it in 3 quarters. The position peaked at $391K in Q3 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Livforsakringsbolaget Skandia reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Livforsakringsbolaget Skandia sold 24,300 Coherus Oncology shares in Q1 2022, an estimated $388K.
  • Livforsakringsbolaget Skandia first reported a position in Coherus Oncology in Q2 2021 and held it in 3 quarters.
  • Livforsakringsbolaget Skandia's Coherus Oncology position peaked at $391K in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2022, filed 21 Jun 2022.